MX2022006452A - Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos. - Google Patents
Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos.Info
- Publication number
- MX2022006452A MX2022006452A MX2022006452A MX2022006452A MX2022006452A MX 2022006452 A MX2022006452 A MX 2022006452A MX 2022006452 A MX2022006452 A MX 2022006452A MX 2022006452 A MX2022006452 A MX 2022006452A MX 2022006452 A MX2022006452 A MX 2022006452A
- Authority
- MX
- Mexico
- Prior art keywords
- ion channel
- channel modulators
- methods
- disease
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se refiere, en parte, a composiciones o formas de dosificación que comprenden compuestos de heteroarilo fusionado útiles para prevenir y/o tratar una enfermedad o afección relacionada con la función anómala de un canal de ion sodio sensible al voltaje, por ejemplo, corriente de sodio anormal tardía/constante. Los métodos para tratar una enfermedad o afección relacionada con la función anómala de un canal de ion sodio que incluye trastornos neurológicos (p. ej., síndrome de Dravet, epilepsia), dolor, trastornos neuromusculares, cefalalgia autonómica trigeminal (TAC), migraña, neuropatía craneal o neuropatía craneal múltiple y depresión cortical propagada (CDS) también se proporcionan en la presente descripción. En otro aspecto, la presente invención proporciona un método para fabricar moduladores de canales de iones.
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962941322P | 2019-11-27 | 2019-11-27 | |
| US201962941319P | 2019-11-27 | 2019-11-27 | |
| US202063001906P | 2020-03-30 | 2020-03-30 | |
| US202063001801P | 2020-03-30 | 2020-03-30 | |
| US202063028229P | 2020-05-21 | 2020-05-21 | |
| US202063082864P | 2020-09-24 | 2020-09-24 | |
| US202063082857P | 2020-09-24 | 2020-09-24 | |
| PCT/US2020/062317 WO2021108625A1 (en) | 2019-11-27 | 2020-11-25 | Formulations of ion channel modulators and methods of preparation and use of ion channel modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006452A true MX2022006452A (es) | 2022-07-11 |
Family
ID=76130400
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006452A MX2022006452A (es) | 2019-11-27 | 2020-11-25 | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20230348466A1 (es) |
| EP (1) | EP4065114A4 (es) |
| JP (1) | JP2023504038A (es) |
| KR (1) | KR20220121238A (es) |
| CN (1) | CN115038442A (es) |
| AU (1) | AU2020392128A1 (es) |
| BR (1) | BR112022010329A2 (es) |
| CA (1) | CA3163091A1 (es) |
| CL (1) | CL2022001384A1 (es) |
| CO (1) | CO2022008769A2 (es) |
| EC (1) | ECSP22049650A (es) |
| IL (1) | IL293264A (es) |
| MX (1) | MX2022006452A (es) |
| PE (1) | PE20221280A1 (es) |
| SA (1) | SA522432737B1 (es) |
| WO (1) | WO2021108625A1 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3548033T3 (fi) | 2016-11-28 | 2024-07-10 | Praxis Prec Medicines Inc | Yhdisteitä ja menetelmiä niiden käyttämiseksi |
| WO2018148745A1 (en) | 2017-02-13 | 2018-08-16 | Praxis Precision Medicines , Inc. | Compounds and their methods of use |
| US11278535B2 (en) | 2017-08-15 | 2022-03-22 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| WO2019232209A1 (en) | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| US11773099B2 (en) | 2019-05-28 | 2023-10-03 | Praxis Precision Medicines, Inc. | Compounds and their methods of use |
| US11505554B2 (en) | 2019-05-31 | 2022-11-22 | Praxis Precision Medicines, Inc. | Substituted pyridines as ion channel modulators |
| US11279700B2 (en) | 2019-05-31 | 2022-03-22 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| JP2023503343A (ja) * | 2019-11-26 | 2023-01-27 | プラクシス プレシジョン メディシンズ， インコーポレイテッド | イオンチャネルモジュレーター |
| MX2022006452A (es) * | 2019-11-27 | 2022-07-11 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos. |
| GB2597320A (en) * | 2020-07-20 | 2022-01-26 | Gw Res Ltd | Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| WO2009100380A1 (en) | 2008-02-06 | 2009-08-13 | Cv Therapeutics, Inc. | Use of ranolazine for treating pain |
| FI3548033T3 (fi) | 2016-11-28 | 2024-07-10 | Praxis Prec Medicines Inc | Yhdisteitä ja menetelmiä niiden käyttämiseksi |
| WO2019232209A1 (en) * | 2018-05-30 | 2019-12-05 | Praxis Precision Medicines, Inc. | Ion channel modulators |
| MX2022006452A (es) * | 2019-11-27 | 2022-07-11 | Praxis Prec Medicines Inc | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos. |
| EP4514347A1 (en) * | 2022-04-26 | 2025-03-05 | Praxis Precision Medicines, Inc. | Treatment of neurological disorders |
-
2020
- 2020-11-25 MX MX2022006452A patent/MX2022006452A/es unknown
- 2020-11-25 PE PE2022000972A patent/PE20221280A1/es unknown
- 2020-11-25 CN CN202080093999.2A patent/CN115038442A/zh active Pending
- 2020-11-25 KR KR1020227021534A patent/KR20220121238A/ko active Pending
- 2020-11-25 EP EP20893872.0A patent/EP4065114A4/en active Pending
- 2020-11-25 IL IL293264A patent/IL293264A/en unknown
- 2020-11-25 WO PCT/US2020/062317 patent/WO2021108625A1/en active Application Filing
- 2020-11-25 JP JP2022530876A patent/JP2023504038A/ja active Pending
- 2020-11-25 CA CA3163091A patent/CA3163091A1/en active Pending
- 2020-11-25 BR BR112022010329A patent/BR112022010329A2/pt unknown
- 2020-11-25 AU AU2020392128A patent/AU2020392128A1/en active Pending
- 2020-11-25 US US17/780,570 patent/US20230348466A1/en active Pending
-
2022
- 2022-05-26 SA SA522432737A patent/SA522432737B1/ar unknown
- 2022-05-26 CL CL2022001384A patent/CL2022001384A1/es unknown
- 2022-06-23 CO CONC2022/0008769A patent/CO2022008769A2/es unknown
- 2022-06-23 EC ECSENADI202249650A patent/ECSP22049650A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SA522432737B1 (ar) | 2024-01-03 |
| KR20220121238A (ko) | 2022-08-31 |
| CA3163091A1 (en) | 2021-06-03 |
| CO2022008769A2 (es) | 2022-07-19 |
| CN115038442A (zh) | 2022-09-09 |
| EP4065114A4 (en) | 2023-12-20 |
| PE20221280A1 (es) | 2022-09-05 |
| WO2021108625A1 (en) | 2021-06-03 |
| ECSP22049650A (es) | 2022-07-29 |
| IL293264A (en) | 2022-07-01 |
| CL2022001384A1 (es) | 2023-03-10 |
| US20230348466A1 (en) | 2023-11-02 |
| BR112022010329A2 (pt) | 2022-08-16 |
| EP4065114A1 (en) | 2022-10-05 |
| AU2020392128A1 (en) | 2022-06-09 |
| JP2023504038A (ja) | 2023-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022006452A (es) | Formulaciones de moduladores de canales ionicos y metodos de preparacion y uso de moduladores de canales ionicos. | |
| MX2020012838A (es) | Moduladores de los canales ionicos. | |
| MX2021003634A (es) | Moduladores de canales de iones. | |
| SA522432719B1 (ar) | مُنظِمات قناة أيونية | |
| MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
| UA74419C2 (uk) | Заміщені піридини та їх застосування як антагоністів рецептору метаботропного глутамату | |
| EP4397308A3 (en) | Compounds and their methods ofuse | |
| PH12020552092A1 (en) | Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease | |
| MX2021003706A (es) | Tratamiento del temblor esencial usando (r)-2-(4-isopropilfenil)-n -(1-(5-(2,2,2- trifluoroetoxi)piridin-2-il)etil)acetamida. | |
| WO2006015775A3 (en) | Egfr kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | |
| MX2022006807A (es) | Análogos de rapamicina y usos de estos. | |
| MX2022013595A (es) | Metodos de uso de moduladores del canal de calcio tipo t. | |
| MX2022002597A (es) | Métodos de tratamiento de la epilepsia usando los métodos. | |
| MX2021008510A (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina. | |
| MX2023001296A (es) | Composiciones y metodos para tratar enfermedades y trastornos. | |
| CR20230408A (es) | Compuestos moduladores de gcn2 y usos de los mismos | |
| ZA202211253B (en) | Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases | |
| AU2020264106A8 (en) | Small molecule bromodomain inhibitors and uses thereof | |
| MX2023015102A (es) | Oligonucleotidos antisentido pikfyve. | |
| CR20230223A (es) | Composiciones farmacéuticas de un inhibidor de cinasa | |
| PL1732926T3 (pl) | Inhibitory kinezyn motorycznych | |
| CR20220231A (es) | Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria | |
| PH12022552553A1 (en) | Substituted 3-phenoxyazetidin-1-yl-pyrazines having gpr52 agonistic activity | |
| MX2023001445A (es) | Compuestos de piridazina 6-sustituidos como degradadores de smarca2 y/o smarca4. | |
| WO2013181391A3 (en) | 7-disubstituted-phenyl tetracycline derivatives |